{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:02:53Z","timestamp":1791194573357,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.jhep.2012.09.006","type":"journal-article","created":{"date-parts":[[2012,9,16]],"date-time":"2012-09-16T09:02:28Z","timestamp":1347786148000},"page":"81-88","source":"Crossref","is-referenced-by-count":89,"title":["Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study"],"prefix":"10.1016","volume":"58","author":[{"given":"Aziz","family":"Zaanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Williet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hebbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienhan Sandrine","family":"Dabakuyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Fartoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Touraj","family":"Mansourbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rosmorduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Cattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bonnetain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Ta\u00efeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2012.09.006_b0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhep.2012.09.006_b0010","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2012.09.006_b0015","first-page":"291","article-title":"Steatosis and hepatocellular carcinoma risk","volume":"9","author":"Smedile","year":"2005","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jhep.2012.09.006_b0020","doi-asserted-by":"crossref","first-page":"x308","DOI":"10.1093\/annonc\/mdl279","article-title":"Medical treatments for hepatocellular carcinoma (HCC): what\u2019s next?","volume":"17","author":"Taieb","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2012.09.006_b0025","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.seminoncol.2007.01.007","article-title":"Hepatocellular carcinoma (HCC): an update","volume":"34","author":"Rougier","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jhep.2012.09.006_b0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cct.2009.08.002","article-title":"Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design","volume":"31","author":"Hsu","year":"2010","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jhep.2012.09.006_b0035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2012.09.006_b0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2012.09.006_b0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1470-2045(04)01508-6","article-title":"Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum","volume":"5","author":"Burroughs","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2012.09.006_b0050","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.11869","article-title":"Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules","volume":"98","author":"Taieb","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2012.09.006_b0055","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/cncr.23489","article-title":"Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study","volume":"112","author":"Asnacios","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2012.09.006_b0060","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/cncr.22532","article-title":"Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study","volume":"109","author":"Louafi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2012.09.006_b0065","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejca.2005.09.034","article-title":"Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level","volume":"42","author":"Boige","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2012.09.006_b0070","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2005.04.9130","article-title":"Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma","volume":"24","author":"Zhu","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2012.09.006_b0075","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.09.006_b0080","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jnci\/82.12.1046","article-title":"Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate","volume":"82","author":"Caussanel","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2012.09.006_b0085","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.ejca.2004.02.027","article-title":"Systemic therapy for advanced hepatocellular carcinoma: a review","volume":"40","author":"Nowak","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2012.09.006_b0090","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2006.08.4046","article-title":"Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin","volume":"25","author":"Gish","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2012.09.006_b0095","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L","article-title":"Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial","volume":"62","author":"Lai","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2012.09.006_b0100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.25578","article-title":"Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study","volume":"117","author":"Lombardi","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2012.09.006_b0105","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.4008","article-title":"Phase III study of oxaliplatin plus 5-fluorouracil\/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients","volume":"28","author":"Qin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2012.09.006_b0110","first-page":"1676","article-title":"Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma","volume":"5","author":"Leung","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2012.09.006_b0115","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/jnci\/dji315","article-title":"A randomized phase III study of doxorubicin versus cisplatin\/interferon alpha-2b\/doxorubicin\/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma","volume":"97","author":"Yeo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2012.09.006_b0120","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000093007","article-title":"Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma","volume":"70","author":"Hebbar","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.jhep.2012.09.006_b0125","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/sj.bjc.6601369","article-title":"Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma","volume":"89","author":"Guan","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2012.09.006_b0130","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00000421-200204000-00021","article-title":"Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients","volume":"25","author":"Alexandre","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jhep.2012.09.006_b0135","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<410::AID-CNCR8>3.0.CO;2-P","article-title":"A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma","volume":"86","author":"Stuart","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2012.09.006_b0140","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/annonc\/mdn030","article-title":"Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials","volume":"19","author":"Collette","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2012.09.006_b0145","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2010.06.015","article-title":"Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting","volume":"54","author":"Tournoux-Facon","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.09.006_b0150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3748\/wjg.v8.i2.193","article-title":"The prognostic significance of clinical and pathological features in hepatocellular carcinoma","volume":"8","author":"Qin","year":"2002","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2012.09.006_b0155","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1634\/theoncologist.2009-0038","article-title":"Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma","volume":"14","author":"Vora","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2012.09.006_b0160","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2008.18.8151","article-title":"New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy","volume":"27","author":"Chan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2012.09.006_b0165","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/hep.20486","article-title":"Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score","volume":"40","author":"Kudo","year":"2004","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812006952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812006952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T20:10:19Z","timestamp":1562184619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827812006952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0168827812006952"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2012.09.006","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}